The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics

被引：96

作者：

Rodby, RA

Rohde, RD

Clarke, WR

Hunsicker, LG

Anzalone, DA

Atkins, RC

Ritz, E

Lewis, EJ

机构：

[1] Section of Nephrology, Department of Medicine, Rush Medical College, Chicago, IL

[2] Division of Biostatistics, Department of Preventive Medicine, University of Iowa, Iowa City, IA

[3] Bristol Myers Squibb P., Princeton, NJ

[4] Monash Medical Centre, Clayton, Vic.

[5] University of Heidelberg, Heidelberg

[6] Rush-Presbyt. St. Luke's Med. Center, Chicago, IL 60612

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2000年 / 15卷 / 04期

关键词：

Angiotensin II receptor antagonist; Diabetic nephropathy; Renoprotection; Type II diabetes;

D O I：

10.1093/ndt/15.4.487

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Background. Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin-angiotensin system in type II diabetic patients is not defined. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), studying the effect of the angiotensin II receptor antagonist irbesartan on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension. Here we report the study design and baseline patient characteristics. Methods. To qualify, hypertensive type II patients, age 30-70 years, must have a 24 h urinary protein excretion of > 900 mg and a serum creatinine 90-265 μmol/l (1.0-3.0 mg/dl) in women and 110-265 μmol/l (1.2-3.0 mg/dl) in men. Three treatment arms include irbesartan, placebo and amlodipine, with every attempt made to achieve similar blood pressure levels in all treatment arms. A total of 1650 patients will be enrolled utilizing ~225 clinics worldwide. The primary outcome measure is time to event to the composite end-point of doubling of serum creatinine, end-stage renal disease or death. The secondary outcome measure is time to composite end-point of fatal or non-fatal cardiovascular events. The average length of patient follow-up is expected to be ~36 months. Results. The baseline characteristics of the study subjects are: age 59 ± 8 years, duration of diabetes 15 ± 9 years, height 168 ± 11 cm (5 ft 6 in), weight 87 ± 19 kg (192 lb), body mass index 31 ± 7 kg/m2, blood pressure 156 ± 18 mmHg/85 ± 11 mmHg, serum creatinine 150 ± 53 μmol/l (1.7 ± 0.6 mg/dl), creatinine clearance 66 ± 34 ml/min and 24 h urine protein 4.0 ± 3.5 g/day.

引用

页码：487 / 497

页数：11

共 24 条

[1]

USRDS 1998 Annual Data Report, (1998)

[2]

Breyer J.A., Therapeutic interventions for nephropathy in type I diabetes mellitus, Semin Nephrol, 17, pp. 114-123, (1997)

[3]

Rodby R.A., Type II diabetic nephropathy: Its clinical course and therapeutic implications, Semin Nephrol, 17, pp. 132-147, (1997)

[4]

Kasiske B.L., Kalil R.S.N., Ma J.Z., Liao M., Keane W.F., Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis, Ann Intern Med, 118, pp. 129-138, (1993)

[5]

Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy, N Eng J Med, 329, pp. 1456-1462, (1993)

[6]

Viberti G., Mogensen C.K., Groop L.C., Pauls J.K., Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria, J Am Med Assoc, 271, pp. 275-279, (1994)

[7]

Mathiesen E.R., Hommel K., Giese J., Parving H.H., Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria, Br Med J, 303, pp. 81-87, (1991)

[8]

Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M., Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients, Ann Intern Med, 118, pp. 577-581, (1993)

[9]

Rodby R.A., Antihypertensive treatment in nephropathy of type 11 diabetes: Role of the pharmacologic blockade of the renin angiotensin system, Nephrol Dial Transplant, 12, pp. 1095-1096, (1997)

[10]

Lachin J., Foulkes M., Evaluation of sample size and power for analyses of survival with allowance for nonuniform patients entry, losses to follow-up, noncompliance, and stratification, Biometrics, 42, pp. 507-519, (1986)

← 1 2 3 →